Skip to content
Search

Latest Stories

RCGP urges NHS England to confirm TERS funding for 2025/26

TERS funding 2025-26
TERS scheme attract GP trainees to economically disadvantaged areas (gettyimages)

With the vital funding yet to be confirmed, the College fears there is a “real danger” that it could be cut from April  

The Royal College of GPs (RCGP) has warned that patients in deprived areas could face even greater difficulty accessing GP services if funding for the Targeted Enhanced Recruitment Scheme (TERS) is withdrawn.

In a letter to NHS England, the College is calling for confirmation that TERS will be extended for 2025/26 and beyond.


The scheme, launched in 2016, was designed to attract GP trainees to economically disadvantaged areas, where healthcare provision has historically been inadequate.

TERS offers a one-off payment of £20,000 to GP trainees who commit to working in hard-to-recruit-to locations.  Over the years, the scheme has successfully recruited over 2,000 GPs.

However, with funding for 2025/26 yet to be confirmed, the RCGP is worried that it could be cut from April.

The College has expressed concern that discontinuing the scheme could “make it even more difficult to recruit GPs to work in deprived and under-doctored areas where patients are already significantly disadvantaged compared to those in more affluent areas of the country.”

Highlighting the UK-wide workforce crisis, RCGP pointed out that in the most deprived areas of England, there are 2,450 patients per full time, fully qualified GP – over 300 more patients per GP than in more affluent areas of the country.

The areas with the highest numbers of places available through the TERS scheme in 2024/25 were Durham and Tees Valley (60), Dewsbury, Pontefract & Wakefield (47) and Sherwood Forest (36).

Professor Kamila Hawthorne, chair of the RCGP, expressed her concerns: “It’s alarming to see a scheme that has provided our patients with much-needed access to GPs now under threat.”

“The TERS has successfully attracted thousands of GP trainees to work in areas that they might previously not have considered, and which desperately need more GPs.

“It has led to clear benefits, including improved patient access, continuity of care, and long-term workforce retention.”

Hawthorne emphasised that cutting the scheme would be a “major step backwards” for the government’s manifesto commitment to halve the gap in healthy life expectancy across the UK.

She noted that the scheme not only encourages GP trainees to take roles in more deprived areas of the country but also put down roots and become part of the community.

“The continuation of TERS is important if we are to attract and retain GPs in these areas and truly tackle health inequalities for our patients,” she added.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less